Ananda Developments - Invitation to Investor Evening
Announcement provided by
Ananda Developments Plc · ANA11/07/2024 07:00
![](https://tracker.live.rns-distribution.com/track.live-rns/5261065_d9353a075fe0b610698e373da828b7e4.png)
ANANDA DEVELOPMENTS PLC
("Ananda" or the "Company")
Investor Evening
Ananda Developments plc (AQSE: ANA), a company focused on becoming a leading provider of regulator approved CBD-based medicines for chronic inflammatory pain conditions, is pleased to announce its participation in "The Pub Test" Investor Evening. This event is co-hosted by the Aquis Exchange and InvestorHub and will take place on Wednesday, 17th July 2024 at Samuel Pepys, Stew Ln,
The Company's CEO, Melissa Sturgess, will engage in a fireside conversation designed especially for private investors. This setting offers a unique opportunity for attendees to interact directly with company executives, ask questions, and network with fellow investors.
Ananda's CEO, Melissa Sturgess, commented: "We look forward to meeting and engaging with interested parties, shareholders, potential shareholders, and stakeholders. This event is a fantastic opportunity to share our vision and answer any questions investors may have."
All attendees will have the chance to network over drinks and a buffet.
To register for the event, please use the following link: https://events.humanitix.com/the-pub-test-or-london-july-4-2024
For more information please contact:
InvestorHub Engage with us directly at Ananda Developments Investor Hub
|
Sign up at |
ANANDA DEVELOPMENTS PLC Chief Executive Officer Melissa Sturgess Executive Director Jeremy Sturgess-Smith
|
+44 (0)7463 686 497 ir@anandadevelopments.com |
SP ANGEL CORPORATE FINANCE LLP Corporate Finance Richard Morrison Caroline Rowe
|
+44 (0)20 3470 0470 |
Corporate Broking Abigail Wayne Rob Rees
|
|
Yellow Jersey PR Charles Goodwin Zara McKinlay |
+44 (0)20 3004 9512 |
About Ananda Developments
Ananda is an AQSE-listed company whose ambition is to be a leading provider of cannabinoid-based medicines for the treatment of complex, chronic inflammatory pain conditions.
For further information on the Company visit https://anandadevelopments.com/ or sign up at
https://investors.anandadevelopments.com/s/a66906.
https://investors.anandadevelopments.com/link/8r6koP
END
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.